Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,738
datasets available to search
ShareScore release 0.9.0
Dataset results
2,738 results for “Multiple Sclerosis”
Shifts Multiple Sclerosis Lesion Segmentation Dataset Part 2
<p>This archive contains part 2 of Shift Benchmark on Multiple Sclerosis lesion segmentation data. This dataset is provided by the Shifts Project to enable assessment of the robustness of models to distributional shift and the quality of their uncertainty estimates. This part is contains data collected from several different sources and distributed under a CC BY NC SA 4.0 license. Part 1 of the data is available <a href="https://zenodo.org/record/7051658">here</a>. A full description of the benchmark is available in https://arxiv.org/pdf/2206.15407. To find out more about the Shifts Project, please visit https://shifts.ai .</p>
Transcriptomic analyses of normal-appearing CNS white matter from multiple sclerosis donors reveal subtype-specific molecular signatures of disease (REVISED)
<p>Datasets of bulk RNA-sequencing of NAWM from MS donors + supplementary images of RNA deconvolution of cell trajectories</p>
Gregory-MS: list of research papers relevant/not relevant for Multiple Sclerosis research (for machine learning training)
<p>This dataset represents the list of research papers' data that was used to train and test different machine learning algorithms in the Gregory-MS project. The list includes the title and abstract (when available) of the research papers and an annotated field (relevant) that specifies if the given research paper is relevant or not for multiple sclerosis research.</p>
Research data supporting "Correlated heterospectral lipidomics for biomolecular profiling of remyelination in multiple sclerosis"
<p>Research data supporting the paper:</p> <p>Bergholt, M.S. et al., "Correlated heterospectral lipidomics for biomolecular profiling of remyelination in multiple sclerosis", ACS Central Science, 2017, DOI: 10.1021/acscentsci.7b00367.</p>
Link to Dataset related to article "Interpreting Non-coding Genetic Variation in Multiple Sclerosis Genome-Wide Associated Regions"
<p>Link to Dataset related to article "Interpreting Non-coding Genetic Variation in Multiple Sclerosis Genome-Wide Associated Regions"</p> <p>Multiple sclerosis (MS) is the most common neurological disorder in young adults. Despite extensive studies, only a fraction of MS heritability has been explained, with association studies focusing primarily on protein-coding genes, essentially for the difficulty of interpreting non-coding features. However, non-coding RNAs (ncRNAs) and functional elements, such as super-enhancers (SE), are crucial regulators of many pathways and cellular mechanisms, and they have been implicated in a growing number of diseases. In this work, we searched for possible enrichments in non-coding elements at MS genome-wide associated loci, with the aim to highlight their possible involvement in the susceptibility to the disease. We first reconstructed the linkage disequilibrium (LD) structure of the Italian population using data of 727,478 single-nucleotide polymorphisms (SNPs) from 1,668 healthy individuals. The genomic coordinates of the obtained LD blocks were intersected with those of the top hits identified in previously published MS genome-wide association studies (GWAS). By a bootstrapping approach, we hence demonstrated a striking enrichment of non-coding elements, especially of circular RNAs (circRNAs) mapping in the 73 LD blocks harboring MS-associated SNPs. In particular, we found a total of 482 circRNAs (annotated in publicly available databases) vs. a mean of 194 ± 65 in the random sets of LD blocks, using 1,000 iterations. As a proof of concept of a possible functional relevance of this observation, we experimentally verified that the expression levels of a circRNA derived from an MS-associated locus, i.e., hsa_circ_0043813 from the <em>STAT3</em> gene, can be modulated by the three genotypes at the disease-associated SNP. Finally, by evaluating RNA-seq data of two cell lines, SH-SY5Y and Jurkat cells, representing tissues relevant for MS, we identified 18 (two novel) circRNAs derived from MS-associated genes. In conclusion, this work showed for the first time that MS-GWAS top hits map in LD blocks enriched in circRNAs, suggesting circRNAs as possible novel contributors to the disease pathogenesis.</p> <p>GEO database</p> <p>URL: <a href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</a></p> <p>Numero di accesso del dataset: GSE110525</p>
Data platform (genotyping data set) related to ERDF postdoctoral project No. 1.1.1.2/VIAA/4/20/718 "The role of vitamin D gene polymorphisms and its receptors in the modulation of intestinal inflammation in patients with relapsing and progressive forms of multiple sclerosis".
<p><strong>Data platform </strong><strong>(genotyping dataset)</strong> <strong>related to the ERDF postdoctoral project No. </strong><strong>1.1.1.2/VIAA/4/20/718</strong><strong> “</strong><strong>The role of vitamin D and its receptor gene polymorphisms in the modulation of intestinal inflammation in patients with relapsing and progressive forms of multiple sclerosis</strong><strong>”.</strong></p> <p><strong>About the project and gathered data:</strong></p> <p>The dataset contains genotyping data on 289 sex-balanced samples (approximately 60% women / 40% men)) were created at the the multiple sclerosis (MS) Clinic of the Latvian Maritime Medical Center (LMMC) in 2011 (disease duration of 1-51 years); the collection was updated within the framework of the ERDF MS project (2017-2020) and replenished during the ERDF postdoctoral project No. 1.1.1.2/VIAA/4/20/718 “The role of vitamin D and its receptor gene polymorphisms in the modulation of intestinal inflammation in patients with relapsing and progressive forms of multiple sclerosis” (2021-2023).</p> <p>For the <strong>Genotyping dataset </strong>relevant information for each patient from the MS disease cohort, referring to proteasomal gene genetic variations (microsatellites and SNPs): (HSMS006 <em>(PSMA6),</em> HSMS602 <em>(FAM177A1),</em> HSMS701 <em>(KIAA0391)</em>, HSMS702 <em>(KIAA0391)</em> HSMS801 <em>(KIAA0391)</em>, rs11543947<em>(PSMB5), </em>rs2277460 (mi110), rs1048990 (mi8)<em> (PSMA6),</em> rs1048990 (mi8)<em> (PSMA6),</em> rs2295826/rs2295827<em>(PSMC6),</em> rs2348071 <em>(PSMA3),</em> rs2071543, rs9357155 <em>(PSMB8),</em> rs17587<em>(PSMB9),</em> rs74421874 <em>(PSMD9); </em>rs9275596 from HLA region; vitamin D-related genes (VDR and GC) polymorphisms: rs2228570, rs1544410, rs7975232, rs731236 (<em>VDR</em>) and rs7041, rs4588 <em>(GC).</em></p>
A more accurate risk biomarkers recognition for Progressive Multifocal Leukoencephalopathy (PML) caused by Polyomavirus JC in patients with multiple sclerosis during treatment with disease-modifying therapies (DMTs): an ongoing clinical challenge.
<p>The therapeutic scenario for the treatment of MS has recently been characterized by a veritable revolution, which has included the introduction, for the first time, of drug treatment guidelines and the entry, in the therapeutic landscape of the last decade, of numerous new drugs that, in varying but significantly relevant ways, have proven capable of modifying the course of the disease (Disease-Modifying Therapies - DMTs). <br> While the arsenal of available drugs has resulted in advances in efficacy and selectivity, it has also exposed them to the danger of side effects, potentially serious and in some cases even fatal. Among the most important side effects, complications of infectious origin, characterized by cases of viral infection/reactivation, as in the case of JCPyV, the etiologic agent of PML, are the most represented. This study, based on the follow-up of MS patients treated with different DMTs, contributes to implementing the data in the literature regarding a greater understanding of the risks related to the administration of these drugs and more appropriate monitoring of MS treatment. The risk of JCPyV reactivation with Fingolimod and Dimethyl fumarate is lower than the risk of viral reactivation associated with natalizumab.<br> In light of the data obtained, it is possible to conclude that, in the case of natalizumab, testing for JC viruria would seem to be more useful in identifying those patients with a JCPyV-specific humoral response that is not yet detectable. In addition, our results, draw attention to the importance of analyzing the NCCR rearrangements of JCPyV. Indeed, the particular rearrangements found in plasma and PBMCs of patients with RRMS treated with natalizumab could represent an alert of neuroinvasiveness in order to detect early those patients with a higher risk of developing PML. In the case of dimethyl fumarate, it seems likely that monitoring of lymphopenia would identify a higher risk group of patients in whom alternative therapy should be sought. Prolonged lymphopenia, with absolute lymphocyte counts less than 750 lymphocytes/mL, might be the major risk factor for PML although, a greater risk might lie in the loss of CD8+ cells that are crucial for JCPyV control.<br> For fingolimod, this strategy cannot be applied because the number of circulating lymphocytes decreases while the actual lymphocyte function appears largely normal therefore, monitoring viruria and viremia along with identification of the neurotrophic variant of the virus seems a more exploitable means for risk stratification.</p> <p>In conclusion, the results of this study can be considered directly transferable to the National Health System in that, both the monitoring of JCPyV reactivation by viruria and the sequence analysis of viral NCCR and host immune set-up could play the role of translatable biomarkers in clinical practice in order to assess the risk of PML onset. In addition to improving risk stratification of this disease, these biomarkers of viral reactivation and pathogenicity could facilitate timely diagnosis, optimizing the use of health care resources and contributing to the reduction of direct and indirect costs of MS disease.</p> <p>Prezioso Carla was supported by the Italian Ministry of Health (Starting Grant: SG-2018-12366194).</p>
Data pertaining to the published article "Quantitative T1 mapping detects blood-brain barrier breakdown in apparently non-enhancing multiple sclerosis lesions" by Donatelli et al., 2023.
<p>Data pertaining to the published article "Quantitative T1 mapping detects blood-brain barrier breakdown in apparently non-enhancing multiple sclerosis lesions" by Donatelli et al., NeuroImage: Clinical (2023). </p><p>PMID: <strong>37717382; </strong>PMCID: <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10514220/">PMC10514220</a>; DOI: <a href="https://doi.org/10.1016/j.nicl.2023.103509">10.1016/j.nicl.2023.103509</a></p>
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
ClinicalTrials.gov study NCT04667117. IPD Sharing: YES. Countries: 1. Publications: 1.
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
ClinicalTrials.gov study NCT04792567. IPD Sharing: YES. Countries: 1. Publications: 1.
Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
ClinicalTrials.gov study NCT03889639. IPD Sharing: YES. Countries: 10. Publications: 1.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
ClinicalTrials.gov study NCT01892722. IPD Sharing: UNDECIDED. Countries: 25. Publications: 2.
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
ClinicalTrials.gov study NCT01201356. IPD Sharing: YES. Countries: 38. Publications: 1.
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
ClinicalTrials.gov study NCT04410978. IPD Sharing: YES. Countries: 24. Publications: 1.
Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis
ClinicalTrials.gov study NCT03594487. IPD Sharing: YES. Countries: 1. Publications: 10.
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
ClinicalTrials.gov study NCT02792231. IPD Sharing: YES. Countries: 30. Publications: 4.
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
ClinicalTrials.gov study NCT02660359. IPD Sharing: YES. Countries: 16. Publications: 1.
A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
ClinicalTrials.gov study NCT02975349. IPD Sharing: YES. Countries: 8. Publications: 6.
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
ClinicalTrials.gov study NCT04411641. IPD Sharing: YES. Countries: 31. Publications: 1.
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
ClinicalTrials.gov study NCT02792218. IPD Sharing: YES. Countries: 29. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.